Learning Objectives

All Lectures will be 20 minutes with 10 minutes for discussion

Thursday PM

• To understand the biology of irritable bowel syndrome
• To understand neural regulation of inflammation
• To understand potential therapies for IBD that involve neural regulation
• To understand the physiology and role of sleep and circadian rhythms in
• the course of IBD
• To understand brain structural and functional changes in IBD and in
• persons with IBD and increased fatigue
• To understand the role of the gut microbiome in celiac disease

Friday

• To learn about the use of EUS in assessing liver fibrosis and portal
• pressure measurement
• To learn about techniques in endoscopic removal of large gastrointestinal
• masses
• To understand the utility of ERCP in managing pancreatitis
• To learn how artificial intelligence can be harnessed in gastroenterology
• To learn how virtual reality can be used therapeutically in
• gastroenterology
• To learn what optimal, holistic, cost effective care in IBD management entails
• To learn what early life risk factors are in IBD
• To develop an approach to therapeutic decision making in Crohn’s disease
• To develop an approach to therapeutic decision making in ulcerative colitis

Registration fee for practicing physicians $187.50 You can register for only June 13, June 14 or both days

Section 1 programs approved by the CAG for MOC Section 1 credits are eligible for conversion to AMA PRA Category 1 Credits™. This event is an accredited group learning activity (Section 1) as defined by the Maintenance of Certification program of the Royal College, approved by the Canadian Association of Gastroenterology (CAG).

Agenda

Thursday June 13, 2024

1230 Welcome: Charles N. Bernstein, MD, University of Manitoba, Winnipeg, Canada
Moderator: Stephen Collins MD, McMaster University, Hamilton, Canada
1235 – 1305 Lin Chang, MD, UCLA, LA, CA – The biology of Irritable bowel syndrome
1305 – 1335 Valentin A Pavlov, PhD – The vagus nerve and cholinergic signaling in the regulation of inflammation and metabolism
Institute of Bioelectronic Medicine, Feinstein Institutes for Medical Research, Northwell Health ​“Neural regulation of immunity and inflammation”
1335 – 1405 Jean Eric Ghia, PhD, University of Manitoba, Winnipeg, Canada – Electrical and pharmacological therapeutic implications for neural regulation of IBD
1406 – 1436 Ali Keshavarzian MD — Rush Medical College, Chicago, IL – Do Sleep and circadian disruption worsen IBD disease course and symptoms including fatigue?
Break: 1440 – 1500
1500 – 1530 Dr. Jennifer Kornelsen, PhD, University of Manitoba, Winnipeg, Canada – Fatigue in IBD is associated with changes in brain structure and function
1531 – 1601 Elena Verdu, PhD — McMaster University, Hamilton, Canada – Is an altered gut microbiome in celiac disease important?
1601 – 1645 Stephen Collins, MD, McMaster University, Hamilton, Canada – Panel discussion

Friday June 14, 2024

0825 – 0830 Welcome Charles N. Bernstein, MD, University of Manitoba, Winnipeg, Canada
Moderator: Dana Moffatt, MD, University of Manitoba Winnipeg, Canada
0830 – 0900 David Diehl MD, Geisinger Medical Center, Dansville PA – The new world of endo-hepatology
0900 – 0930 Jeff Mosko, MD, University of Toronto, Toronto Canada – Selecting Lesions for EMR vs ESD in the West
0930 – 1000 D. Nageshwar Reddy MD, DM, Asian Institute for Gastroenterology, Hyderabad,
India – Role of ERCP in management of pancreatitis
1000 – 1030 Tyler Berzin MD, Harvard Medical School, Boston, MA – Co-pilots, ecosystems, and foundation models: the road ahead for AI in GI
Break 1030 – 1050
1050 – 1120 Brennan Spiegel, Cedars Sinai Medical Center, LA, CA – Virtually Better: VR as a New Clinical Tool in Gastroenterology
1120 – 1230 Dana Moffatt University of Manitoba – Panel Discussion
1230 – 1330-Lunch
Moderator: Seth Shaffer, MD, University of Manitoba, Winnipeg, Canada
1330 – 1400 Jane Andrews MBBS, University of Adelaide, Adelaide, Australia – National Benchmarking in IBD; Care management and documentation: Lessons from Australia
1400 – 1430 Siew C Ng, MBBS, PhD The Chinese University of Hong Kong, Hong Kong – Early life factors/​diet/​microbiome and IBD risk
1430 – 1500 Remo Panacionne, MD University of Calgary, Calgary, Canada – What is first line and what is second line therapy in Crohns disease
1500 – 1530 David Rubin MD, University of Chicago, Chicago, IL – What is first line and what is second line therapy in ulcerative colitis
1530 – 1550 break
1550 – 1700 Seth Shaffer, MD, University of Manitoba, Winnipeg, MB – Panel discussion